Advertisement

Topics

Charcot-Marie-Tooth Association Company Profile

18:00 EDT 26th September 2017 | BioPortfolio


News Articles [1020 Associated News Articles listed on BioPortfolio]

Flex???s Phase II Trial With FLX-787 In Charcot-Marie-Tooth Endorsed By

  Life Sciences Jobs   ...

Flex Pharma???s Phase II Trial With FLX-787 In Charcot-Marie-Tooth Endorsed By

  Life Sciences Jobs   ...

Acceleron Pharma Announces First Patient Treated In Phase II Clinical Trial Of ACE-083 In Charcot-Marie-Tooth Disease

  Life Sciences Jobs   ...

PHARNEXT Amends The Protocol Of The International Pivotal Phase III Trials Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A

  Life Sciences Jobs   ...

PHARNEXT Announces That The Recommends Continuing The Ongoing Phase III Trial Of PXT3003 For Charcot-Marie-Tooth Disease Type 1A

  Life Sciences Jobs   ...

Pharnext Amends the Protocol of the International Pivotal Phase 3 Trials of PXT3003 for Charcot-Marie-Tooth Disease Type 1A

- No safety concern and PXT3003 development milestones remain unchanged - Regulatory News: Pharnext SA (Paris:ALPHA) (FR00111911287 ALPHA), a biopharmaceutical company pioneering a new approach to...

Pharnext ändert das Protokoll der internationalen Phase-3-Zulassungsstudien mit PXT3003 zur Behandlung der Charcot-Marie-Tooth-Erkrankung Typ 1A

- Keine Sicherheitsbedenken und die Entwicklungsmeilensteine zu PXT3003 bleiben unverändert - Pharnext SA (Paris:ALPHA) (FR00111911287 ALPHA), ein biopharmazeutisches Unternehmen mit einem neuarti...

Tasly/Pharnext JV licenses TCM combo compounds to ownership companies

Concurrent with its gaining rights to Pharnext SA's Phase III Charcot-Marie-Tooth disease Type 1A (CMT1A) compound (PXT3003), the 70/30 JV created by Tasly Pharmaceutical Co. Ltd. (majority owner) and...

PubMed Articles [2771 Associated PubMed Articles listed on BioPortfolio]

Charcot-Marie-Tooth Disease Type 1A: Influence of Body Mass Index on Nerve Conduction Studies and on the Charcot-Marie-Tooth Examination Score.

Charcot-Marie-Tooth Disease type 1A (CMT1A) is caused by a duplication of the peripheral myelin protein gene 22 at chromosome 17p11.2-12. There is limited data regarding whether body mass index (BMI) ...

Natural history of Charcot-Marie-Tooth disease during childhood.

To determine the rate of disease progression in a longitudinal natural history study of children with Charcot-Marie-Tooth disease (CMT).

Genetic and clinical characteristics of NEFL-related Charcot-Marie-Tooth disease.

To analyse and describe the clinical and genetic spectrum of Charcot-Marie-Tooth disease (CMT) caused by mutations in the neurofilament light polypeptide gene (NEFL).

Unilateral oculomotor palsy in Charcot-Marie-Tooth disease 1A (CMT 1A).

Charcot-Marie-Tooth disease (CMT) type 1A is the most common form of CMT 1 and one of the autosomal dominant demyelinating hereditary motor and sensory neuropathies (HMSN). Cranial nerves may be frequ...

Different nerve ultrasound patterns in Charcot-Marie-Tooth types and HNPP.

Nerve ultrasound in Charcot-Marie-Tooth disease (CMT) has mostly focused on upper limbs. We performed an evaluation of a large cohort of CMT patients in which we sonographically characterized nerve ab...

Clinical Trials [1586 Associated Clinical Trials listed on BioPortfolio]

Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611)

The purpose of this study is to develop and validate a clinical outcome measure to evaluate disability and disease progression of children 3 years of age and younger (infants and toddlers)...

Effects of Coenzyme Q10 on Charcot-Marie-Tooth Disease

The object of this research is to test the effectiveness of Coenzyme Q10 (CoQ10) on symptoms of weakness, fatigue, and pain in persons with Charcot-Marie-Tooth disease (CMT).In this study ...

Follow up and Observation of Charcot Marie Tooth Disease in Families

The study is aimed to test the hypothesis that there is anticipation in CMT

Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease

This is a multicenter, phase 2 study to evaluate the safety, tolerability, pharmacodynamics (PD), efficacy, and pharmacokinetics (PK) of ACE-083 in patients with CMT1 and CMTX, to be condu...

Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A

All randomised patients with Charcot-Marie-Tooth Type 1A (CMT1A) who completed the primary study CLN-PXT3003-02, i.e. 15-month double-blind treatment with PXT3003 or placebo, will be eligi...

Companies [1277 Associated Companies listed on BioPortfolio]

Charcot-Marie-Tooth Association

Hereditary Neuropathy Foundation

Hereditary Neuropathy Foundation (HNF) is a non-profit 501(c)3 organization whose mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth disease (CMT) and ...

Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. P...

Ella Marie Foundation

The Ella Marie Foundation was founded in 1998 with a simple desire of helping others. Over the past 16 years, that mission has expanded into a cohesive effort to enhance the lives...

Marie Claire

More Information about "Charcot-Marie-Tooth Association" on BioPortfolio

We have published hundreds of Charcot-Marie-Tooth Association news stories on BioPortfolio along with dozens of Charcot-Marie-Tooth Association Clinical Trials and PubMed Articles about Charcot-Marie-Tooth Association for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Charcot-Marie-Tooth Association Companies in our database. You can also find out about relevant Charcot-Marie-Tooth Association Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record